Stelios Papadopoulos - 13 Apr 2023 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
13 Apr 2023
Net transactions value
+$200,000
Form type
4
Filing time
14 Apr 2023, 16:39:06 UTC
Previous filing
17 Jun 2022
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Award $200,000 +222,198 +44% $0.9001 728,388 13 Apr 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated April 13, 2023. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof
F2 Adjusted to reflect 10-to-1 reverse stock split effected June 28, 2022.